ENCLAI Daily · Article of the day 29 Sep 2026 · ENCLAI Editorial

EASL guidance recommends resmetirom or semaglutide for non-cirrhotic MASH with fibrosis stages 2-3

Guideline · decision pathJournal of hepatology · 1 Dec 2026 · PubMed 42805503 · built from the abstract

MASH pharmacotherapy decision path

Follow the path from top to bottom. Text in quotation marks is the guidance’s own wording.

Who this is forthis joint EASL-EASD-EASO guidance provides updated recommendations for the use of resmetirom (80mg/100mg po) and semaglutide (2.4 mg sc weekly) in MASH

Step 1 · Who qualifies for treatment

Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimized comorbidity management.
If
fibrosis stages 2-3
adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy)
Recommended
Pharmacotherapy is recommended for adults with non-cirrhotic MASH and fibrosis stages 2-3 (based on NITs or biopsy), alongside structured lifestyle intervention and optimized comorbidity management.
If
VCTE 10-20 kPaMRE 3.1-5.0 kPaELF 9.8-11.3
VCTE 10-20 kPa, MRE 3.1-5.0 kPa, or ELF 9.8-11.3
Consider
in which pharmacotherapy may be considered

Step 2 · How to choose the agent

Therapy selection should be individualized according to preferences, potential risks, and cardio-renal-metabolic profile, including presence of obesity, type 2 diabetes (T2D), cardiovascular, and chronic kidney disease.
If
adults with obesity or T2D as well as with established cardiovascular (CV) disease or high CV risk
Preferred
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), may be preferred in adults with obesity or T2D as well as with established cardiovascular (CV) disease or high CV risk because of its cardiometabolic benefits
If
individuals without obesity or those already receiving or intolerant to GLP-1RAs
Preferred
resmetirom may be prioritized in individuals without obesity or those already receiving or intolerant to GLP-1RAs

Step 3 · Monitoring during therapy

Additional recommendations include structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria.
Monitor
structured safety and efficacy monitoring such as nutritional and sarcopenia assessment during semaglutide or use of fibrosis NITs for longitudinal response criteria

Step 4 · Cirrhosis exclusion

If
adults with MASH cirrhosis
Not advised
resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits
Built from the abstract: abstract (PubMed). Every quoted fragment was checked against that text word for word, and the path was reviewed by the ENCLAI Router as a clinician-editor (no major issues (2 minor wording notes)). ENCLAI only arranges the guidance’s own if/then statements.
A decision path is a reading aid, not medical advice. Clinical decisions need the full guidance.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

A joint EASL-EASD-EASO guideline recommends pharmacotherapy with resmetirom or semaglutide for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis stages 2-3. The guidance advises using non-invasive tests to identify high-risk patients and individualizing therapy based on cardiometabolic profiles.

Who the findings apply to

The recommendation applies to adults with non-cirrhotic MASH and fibrosis stages 2-3, identified by non-invasive tests or biopsy.

Non-invasive tests for hepatic fibrosis, such as vibration-controlled transient elastography, magnetic resonance elastography, or enhanced liver fibrosis score, can replace liver biopsy to identify high risk for major adverse liver-related outcomes.

Specific thresholds for high risk include vibration-controlled transient elastography of 10-20 kPa, magnetic resonance elastography of 3.1-5.0 kPa, or enhanced liver fibrosis score of 9.8-11.3.

In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment until further data establish liver-related benefits.

Why this matters

Adults with MASH are at risk for major adverse liver-related outcomes, including cirrhosis, cancer, and liver transplantation. This guidance provides updated recommendations for treatment candidate selection, initiation, monitoring, and discontinuation following regulatory approval of these agents. It emphasizes that therapy selection should be individualized according to preferences, potential risks, and the presence of obesity, type 2 diabetes, cardiovascular, or chronic kidney disease.

What the study found

The guidance recommends pharmacotherapy for adults with non-cirrhotic MASH and fibrosis stages 2-3 alongside structured lifestyle intervention and optimized comorbidity management.

Semaglutide, a glucagon-like peptide-1 receptor agonist, may be preferred in adults with obesity or type 2 diabetes, as well as those with established cardiovascular disease or high cardiovascular risk, because of its cardiometabolic benefits.

Resmetirom may be prioritized in individuals without obesity or those already receiving or intolerant to glucagon-like peptide-1 receptor agonists.

Recommended doses include resmetirom 80mg or 100mg orally and semaglutide 2.4 mg subcutaneously weekly.

What the result does not establish

Ongoing studies are evaluating the long-term effectiveness of both agents to reduce major adverse liver-related outcomes.

In adults with MASH cirrhosis, the agents should not be used as MASH-targeted treatment until further data establish liver-related benefits.

Additional recommendations include structured safety and efficacy monitoring, such as nutritional and sarcopenia assessment during semaglutide use or the use of fibrosis non-invasive tests for longitudinal response criteria.

Authors’ conclusion

“Ongoing studies are evaluating long-term effectiveness of both agents to reduce MALO. In adults with MASH cirrhosis, resmetirom or semaglutide appear safe but should not be used as MASH-targeted treatment, until further data establish liver-related benefits.”

Study and sources

EASL-EASD-EASO Guidance for the Use of Resmetirom and Semaglutide as MASH-Targeted Therapy

Guidelines & recommendations · Journal of hepatology · 2026-12-01

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.